Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
151
resultados
Última actualización
14/07/2026 [07:49:00]
Resultados 100 a 125 de 151
Resumen de: WO2025101478A1
The presently claimed and described technology provides methods for detecting phosphorylated tau (p-tau)217 in a biological sample using an immunoassay analyzer.
Resumen de: CN122193590A
本申请涉及一种用于评估或诊断多系统萎缩患者的血液生物标志物及其用途。其中的血液生物标志物为α‑Syn、NfL中至少一种与C3的组合。通过该血液生物标志物，能够辅助多系统萎缩患者的早期诊断和连续监测，检测成本低、操作简单、检测速度快、创伤性小、可及性好，适合大多数患者使用，临床应用价值高。
Resumen de: US20260160752A1
0000 A method for co-compartmentalising a cyclic polypeptide with a polynucleotide encoding the cyclic polypeptide, comprising the steps of a) forming a compartment containing a polynucleotide encoding the cyclic polypeptide, b) expressing a polypeptide from the polynucleotide, and c) cyclising the polypeptide. Co-compartmentalised cyclic polypeptides and encoding polynucleotides. Libraries of co-compartmentalised cyclic polypeptide and encoding polynucleotide. Methods for screening libraries of co-compartmentalised cyclic polypeptide and encoding polynucleotide. Incorporation of non-canonical nucleic acids into such libraries.
Resumen de: WO2026119202A1
Provided are a variant of glucagon-like peptide-1 (GLP-1) and use thereof. It has been discovered that GLP-1 can be degraded by an insulin-degrading enzyme (IDE), and degradation sites thereof are identified. Moreover, a GLP-1 variant with enhanced stability is designed, and the cellular secretion level and stability of GLP-1 are improved by regulating the IDE.
Resumen de: US20260160769A1
0000 A detection device and associated systems and methods for detecting analytes from a multiplex reaction are described. In particular, a device for conducting at least one detection reaction using a modified ELISA method including a surface with a detection region and a reference region, a detection sensor, and a light source. The detection device may include a complementary metal-oxide-semiconductor (CMOS) image sensor. The device may be used to measure and report discrete quantities or combinations of discrete analytes, providing information to aid in the prognosis and/or diagnosis of altered states of health in vertebrates.
Resumen de: WO2026118345A1
The present invention provides a rapid, visual, simple, and low-cost immunochromatographic test kit for combined detection of amyloid beta 1-42, NfL, and UCH-L1. The test kit comprises an immunochromatographic test strip, the test strip comprising a sample pad, a conjugate pad, and a nitrocellulose membrane, the conjugate pad comprising microsphere-labeled anti-amyloid beta 1-42, NfL, and UCH-L1 antibody conjugates. Employing combined detection of three markers, amyloid beta 1-42, NfL, and UCH-L1, increases diagnostic accuracy for early detection of Alzheimer's disease and for neurological health.
Resumen de: WO2024246526A1
The present disclosure relates to CD19 CAR-T cell products and methods of treating relapsed or refractory CD19+ haematological malignancies.
Resumen de: US20260158142A1
Provided are engineered cells that include a T cell receptor (TCR) or antigen-binding fragment thereof that binds to amyloid beta, and methods of engineering and using such cells, such as in methods of treatment, diagnosis, and monitoring of therapeutic effectiveness, of diseases or conditions, such as those associated with amyloid beta, e.g., Alzheimer's Disease.
Resumen de: US20260160763A1
0000 This document relates to methods and materials involved in assessing and/or treating mammals having a neurological autoimmune disorder (e.g., a paraneoplastic neurological autoimmune disorder) and/or cancer. For example, methods and materials for detecting anti-neuronal nuclear antibody type 3 (ANNA3) antibodies are provided.
Resumen de: US20260159878A1
0000 Disclosed herein, inter alia, are compositions and methods of use thereof for interrogating a cell.
Resumen de: WO2026121369A1
The present invention provides a method for diagnosing neurodegenerative diseases or providing information for the diagnosis thereof in such a manner that magnetic beads to which a first antibody capable of capturing exosomes such as an anti-CD63 antibody is attached is introduced into the blood of a patient to capture exosomes containing neurodegenerative disease-associated proteins, and then a neurodegenerative disease-associated protein-specific antibody is attached to the captured exosomes to perform detection.
Resumen de: US20260158147A1
0000 Compositions, methods and systems for targeted delivery using one or more shuttles operably linked to one or more cargos (e.g., cargo polypeptides, e.g., cargo oligonucleotides) and subsequent quantification of an abundance of one or more cargos (e.g., proteins) in a mixture (e.g., a complex mixture (e.g., in vivo)) or in a specific cell, tissue, or organ of interest (e.g., in vivo) using barcodes (e.g., peptide barcodes), binders (e.g., polypeptide binders), and binding agents (e.g., phage) are provided herein.
Resumen de: WO2026122090A1
Embodiments of the invention include a system and method of using biomarkers in the diagnosis of Alzheimer's disease. A subject can be screened for Alzheimer's disease based on altered expression of one or more biomarkers in blood, plasma or saliva from the subject. Embodiments include 43 specific mRNA biomarkers to screen or distinguish healthy individuals from individuals affected with Alzheimer's disease. The biomarkers can also be used to determine the prognosis of a subject with the disease and identify early-onset and/or asymptomatic Alzheimer's disease.
Resumen de: WO2026122927A1
Provided are methods for detecting or quantifying tau isoforms in a biological sample. The methods include detecting or quantifying big tau isoforms and small tau isoforms from a sample obtained from a subject. Also provided are methods for treating a subject identified as having or at risk for a neurological disorder based on tau isoforms detected or quantified from a sample from the subject.
Resumen de: WO2026122709A1
Provided herein are, inter alia, methods of inhibiting or reversing aging by inhibiting phosphorylation of eukaryotic translation initiation factor 4E (eIF4E). It is provided herewith that eIF4E protein stability and phosphorylation levels increase during aging and the methods of inhibition of eIF4E phosphorylation provided herein reverse symptoms and features of aging, extend lifespan, and reduce senescence.
Resumen de: WO2026120021A1
The present invention relates to a method for the diagnosis, the prognosis, for monitoring the evolution, or for determining the risk of having or developing neurodegenerative disease in a subject, or for determining the efficacy of a treatment of neurodegenerative disease in a subject. The method comprises detecting the presence of 3-hydroxy capric acid (10:0-3OH), 3-hydroxy lauric acid (12:0-3OH), 3-hydroxy myristic acid (14:0- 3OH), 3-hydroxy palmitic acid (16:0-3OH) and/or 3-hydroxy stearic acid (18:0-3OH) in a sample of biological fluid of said subject.
Resumen de: WO2026122610A1
Methods for making a reconstructed human brain tissue are provided. Also provided are methods for evaluating whether a drug candidate inhibits amyloid deposition.
Resumen de: US20260160682A1
0000 A method is for detecting a chemical messenger within a sample of blood. The method may include flowing the sample of blood over a sensing surface of a plasmonic array biosensor. The sensing surface of the plasmonic array biosensor may have an ssDNA aptamer against the chemical messenger. The method may further include binding the chemical messenger in the sample of blood to the ssDNA aptamer of the plasmonic array biosensor, and detecting the chemical messenger in the sample of blood based upon LSPR altering a reflected optical signal from the plasmonic array biosensor.
Resumen de: WO2026120847A1
The present invention addresses the problem of providing a method for detecting a protein contained in exosomes. The problem is solved by a method for detecting a protein contained in exosomes, the method including a step for subjecting a measurement sample that is an exosome-containing solution separated from a specimen to a proximity elongation assay (PEA) and quantifying a target protein in the sample.
Resumen de: WO2026122584A1
Antisense oligonucleotide strategies, including compositions and methods, for increasing protein levels are provided. Target proteins include but are not limited to tank binding protein kinase 1 (TBK-1 or TBK1), follistatin (FST), and progranulin (PGRN). The compositions and methods described herein are applicable for treatment of neurodegenerative diseases caused by haplo-insufficiency.
Resumen de: WO2026120092A1
The present invention relates to methods for the detection and/or quantification of 3-hydroxylated fatty acids (3-OH HFA or 3-hydroxylated HFA) in a sample; in particular a biological sample. The present invention also relates to methods for the detection and/or quantification of lipopolysaccharides (LPS) in a sample. The present invention further relates to such methods, for diagnosing and/or prognosing a disorder in a subject; and/or for monitoring the evolution of a disorder in a subject, or risk thereof; and/or for determining the efficacy of a treatment or prevention of said disorder in a subject in need thereof.
Resumen de: WO2026120517A1
Described herein is a method of processing and analyzing mass spectrometry data in its original state with minimal to no data reduction for analysis directly by a machine learning classifier. This may be for the purposes of diagnosing, detecting, classifying, predicting, stratifying, screening or monitoring one or more medical conditions or disease states, and discovering biomarker signatures.
Resumen de: US20260159577A1
0000 The present invention provides polypeptides with the ability to bind selectively to damage-associated molecular patterns (DAMPs), and fusion proteins thereof, for use in treatment of uncontrolled inflammation such as that associated with sepsis. More specifically, the present disclosure is drawn to one such fusion protein, Opsonic Peptide 18 (herein after referred to as “OP18”), and its use as a therapeutic to target and reduce the activity of DAMPs thereby providing treatment of uncontrolled inflammation including that associated with sepsis.
Resumen de: WO2026117869A1
Provided herein are methods for inhibiting lysine uptake or limiting its systemic availability is sufficient to decrease pathogenic catabolite production in cells. These methods useful for reducing the accumulation of pathogenic metabolites in pyridoxine-dependent epilepsy (PDE), glutaric acidemia type I (GA1), hyperlysinemia or other lysine catabolic disorders. In particular, L-lysine oxidase (LOX) enzyme may be systemically administered to reduce the accumulation of lysine and pathogenic metabolites. Furthermore, compounds described herein are absorbed by the skin.
Nº publicación: KR20260087123A 11/06/2026
Solicitante:
국립순천대학교산학협력단
Resumen de: KR20260087123A
0001a 4-tert-octylphenol(4-tert-OP)은 환경에서 널리 발견되는 잠재적으로 유해한 물질입니다. 그럼에도 불구하고 4-tert-OP의 생체 내 독성 동태학에 대한 정보는 부족하고 정량적 위험 평가 연구가 시급히 필요합니다. 따라서 우리는 성별 간 4-tert-OP의 독성 동태학과 조직 내 분포의 차이를 정량적으로 식별하는 것을 목표로 했습니다. 이를 위해 수컷과 암컷 쥐에게 10 또는 50 mg/kg의 4-tert-OP를 경구 투여하고 4 또는 8 mg/kg의 4-tert-OP를 정맥 주사한 후 초고성능 액체 크로마토그래피-탠덤 질량 분석법을 사용하여 샘플에 대한 정량적 분석을 수행했습니다. 결과에 따르면 4-tert-OP 혈장 농도 프로필은 성별 간에 차이가 있었습니다. 그러나 4-tert-OP의 위장관을 통한 전신 흡수는 두 성별 모두 노출 후 0.5시간 이내에 발생했습니다. 비록 적지만 소변과 대변에서 4-tert-OP의 배설 비율은 남성이 여성보다 낮았습니다(노출의 0.06-0.08% 대 0.82-1.11%). 4-tert-OP의 조직 분포 패턴에서도 유의한 성별 차이가 확인되었고 전반적으로 남성의 평균 조직 분포는 여성보다 낮았습니다. 두 성별 모두에서 4-tert-OP의 간, 지방, 비장, 신장, 뇌, 폐 분포가 우세했습니다. 공변량 탐색 모델링 접근법은 성별이 성별 간 4-tert-OP 독성동태학의 차이를 설명한다는 것을 보여주
BOPI
Sede Electrónica
